Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of T-20 (Enfuvirtide) with Background Antiretrovirals in HIV-1
NCT00002239Phase 2Completed
- Sponsor
- Roche
- Start
- May 1999
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enfuvirtide in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Roche. Primary endpoints: Safety parameters at 48 weeks and Virologic activity at 48 weeks. Started May 1999; status: completed.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002239.